Anti-Influenza agent 12
Anti-Influenza agent 12 is an orally active inhibitor of influenza A virus infection. Anti-Influenza agent 12 inhibits RIG-I-mediated innate immune signaling and TLR3-mediated signaling pathways. Anti-Influenza agent 12 inhibits NF-κB phosphorylation and downregulates the expression levels of IRF3, ASC, iNOS, IL-4, IL-6, and IFN-α inflammatory genes. Anti-Influenza agent 12 inhibits viral nucleoprotein (NP) and matrix protein 2 (M2) mRNA transcription and protein synthesis. Anti-Influenza agent 12 inhibits virus-induced apoptosis, reduces ROS and NO production, and maintains mitochondrial membrane potential. Anti-Influenza agent 12 exhibits broad-spectrum activity against H1N1 and H3N2 subtypes, reduces viral load, and alleviates lung tissue damage. Anti-Influenza agent 12 can be used for research on influenza A virus infection.
For research use only. We do not sell to patients.
- CAS No.: 3087067-85-1
- Formula: C37H30N2O4S
- Molecular Weight:598.71
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
IL-6 |
IL-4 |
TLR3 |
RIG-I |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDCK | CC50 |
439.10 μM
|
Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
|
42551133 |
| A549 | CC50 |
314.85 μM
|
Cytotoxicity against A549 cells assessed as reduction in cell viability by MTT assay.
Cytotoxicity against A549 cells assessed as reduction in cell viability by MTT assay.
|
42551133 |
| MDCK | EC50 |
2.50 μM
|
Antiviral activity against influenza A virus (A/Weiss/43, H1N1) in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 72 hrs by MTT assay.
Antiviral activity against influenza A virus (A/Weiss/43, H1N1) in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 72 hrs by MTT assay.
|
42551133 |
In Vitro
Anti-Influenza agent 12 (Compound 3g) (72 h) exhibits potent anti-IAV activity against A/Weiss/43 (H1N1) in MDCK cells with an EC50 of 2.50 μM[1].
Anti-Influenza agent 12 reduces viral load in a dose-dependent manner in MDCK cells infected with A/Weiss/43 (H1N1)[1].
Anti-Influenza agent 12 (25-100 μM; 24-72 h) significantly inhibits the mRNA and protein expression of viral NP and M2 genes in IAV-infected MDCK and A549 cells[1].
Anti-Influenza agent 12 (25-100 μM) prevents IAV-induced collapse of mitochondrial membrane potential[1].
Anti-Influenza agent 12 (25-100 μM) exerts anti-apoptotic effects by modulating Bcl-2/Bax and inhibiting the cleavage of Caspase-3 and PARP in IAV-infected cells[1].
Anti-Influenza agent 12 (25-100 μM; 24 h) inhibits IAV-induced ROS production in MDCK cells in a dose-dependent manner[1].
Anti-Influenza agent 12 (25-100 μM; 24 h) reduces IAV-induced NO production in RAW264.7 cells in a dose-dependent manner[1].
Anti-Influenza agent 12 (25-100 μM) broadly blocks the activation of inflammatory signaling pathways at the transcriptional level in IAV-infected A549 cells[1].
Anti-Influenza agent 12 (25-100 μM) decreases RIG-I protein expression and inhibits NF-κB phosphorylation in IAV-infected A549 cells[1].
Anti-Influenza agent 12 (72 h) exhibits low cytotoxicity in MDCK and A549 cells, with CC50 values of 439.10 and 314.85 μM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549 cells
-
Concentration:25, 50, 100 μM
-
Incubation Time:24 h
-
Result:Gradually decreased NP and M2 protein expression bands as concentration increased.
-
Cell Line:MDCK cells
-
Concentration:25, 50, 100 μM
-
Incubation Time:24 h
-
Result:Significantly reduced the intensity of green fluorescent signal.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 5 weeks old)[1]
-
Dosage:25-100 mg/kg/d
-
Administration:i.g.; once daily; 6 days
-
Result:Alleviated clinical symptoms such as listlessness, piloerection, hunchback, loss of appetite, and weight loss.
Reduced viral loads in the lungs as evidenced by decreased mRNA levels of viral NP and M2 genes on days 2, 4, and 6 post-infection.
Reduced NP protein positive staining in lung tissues on day 6.
Reduced the lung index and alleviated pulmonary histopathological damage.
Downregulated mRNA levels of inflammatory genes RIG-I, TLR3, IRF3, ASC, iNOS, IL-4, IL-6, and IFN-α in lung tissues.
Reduced apoptosis in lung tissues.
Chemical Information
-
CAS No. 3087067-85-1
-
Molecular Weight 598.71
-
Formula C37H30N2O4S
-
SMILES
O=C(C1=CC=CC=C1)CC2=C(C3=CC=CC=C3)C(N(S(=O)(C(C=C4)=CC=C4OC)=O)CC5=CC=CC=C5)=NC6=CC=CC=C62
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Influenza agent 12 Related Classifications
HY-189215 Related Classifications
Powered by Bioz
Keywords
- Anti-Influenza agent 12
- 3087067-85-1
- Influenza Virus
- RIG-I-like receptor (RLR)
- Toll-like Receptor (TLR)
- NF-κB
- Interleukin Related
- IFNAR
- Apoptosis
- Reactive Oxygen Species (ROS)
- RAW264.7 cells
- A549 cells
- MDCK cells
- NF-κB phosphorylation
- influenza A virus
- RIG-I-mediated innate immune signaling
- TLR3-mediated signaling pathways
- matrix protein 2
- H1N1
- viral nucleoprotein
- Inhibitor
- inhibitor
- inhibit